Dyslipidaemia is a common complication among HIV-infected children after antiretroviral therapy (ART); however, HIV itself can cause abnormal lipid metabolism. There is limited information of lipid profiles among Asian HIV-infected children naive to ART.
Methods
A total of 274 HIV-infected ART-naive Thai and Cambodian children aged 1-12 years with CD4% between 15% and 24% were included. Patients were fasted for ≥4 h before blood was drawn. Abnormal lipid levels were defined as triglyceride (TG)>130 mg/dl, total cholesterol (TC)>200 mg/dl, low-density lipoprotein (LDL)>130 mg/dl and high-density lipoprotein (HDL)≤40 mg/dl.
Results
The mean (±sd) was 76.6 (33.8) months for age and -1.3 (1.0) for weight Z-score. Mean (±sd) CD4% was 19.9 (4.8) % and HIV RNA was 4.6 (0.6) log10 copies/ml. The median (±sd) fasting time was 13.0 (2.7) h. Mean (±sd) for lipids were 116 (62) mg/dl for TG, 139 (29) mg/dl for TC, 73 (29) mg/dl for LDL and 45 (19) mg/dl for HDL. Overall 63.9% had dyslipidaemia with hypertriglyceridaemia and hypo-HDL being the most common (28% and 45%, respectively), while 2% had hypercholesterolaemia or hyper-LDL. After adjusting for age, having HIV RNA>5 log10 copies/ml was associated with hypo-HDL with ORs of 8.1 (95% CI 2.7–24.3).
Conclusions
Up to two-thirds of ART-naive, HIV-infected Asian children with mild-to-moderate immune suppression had dyslipidaemia. Low HDL was the most common and was associated with high HIV viraemia. The long-term consequence of low HDL deserves further investigation in children.
References
1.
AldrovandiG.M., LindseyJ.C., JacobsonD.L.Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS2009; 23: 661–672.
2.
ChantryC.J., HughesM.D., AlveroC.Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics2008; 122: e129–e138.
3.
CarterR.J., WienerJ., AbramsE.J.Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr2006; 41: 453–460.
4.
FarleyJ., GonaP., CrainM.Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4–19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr2005; 38: 480–487.
5.
GrunfeldC., KotlerD.P., HamadehR.Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med1989; 86: 27–31.
6.
GrunfeldC., PangM., DoerrlerW.Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab1992; 74: 1045–1052.
7.
GrunfeldC., TienP.Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis2003; 37Suppl 2: S43–S46.
8.
El-SadrW.M., MullinC.M., CarrA.Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med2005; 6: 114–121.
9.
Friis-MøllerN., ReissP., El-SadrW.Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study.13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Abstract 144.
10.
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med2006; 355: 2283–2296.
11.
McComseyG.A., O'RiordanM., HazenS.L.Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS2007; 21: 921–927.
12.
National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics1992; 89: 495–501.
13.
National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation2002; 106: 3143–3421.
14.
McCrindleB.W., UrbinaE.M., DennisonB.A.Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation2007; 115: 1948–1967.
15.
CerviaJ.S., ChantryC.J., HughesM.D.Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy. Pediatr Infect Dis J2010; 29: 1118–1122.
16.
AurpibulL., PuthanakitT., LeeB.Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther2007; 12: 1247–1254.
17.
BottonJ., HeudeB., KettanehA.Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sante II study. Metabolism2007; 56: 614–622.
18.
American Diabetes Association.Type 2 diabetes in children and adolescents. Diabetes Care2000; 23: 381–389.
19.
RaghavanS., ChenL., El-SadrW.Prevalence and factors associated with fasting hypercholesterolemia, hypertriglyceridemia, and hyperglycemia in ethnically diverse antiretroviral naive patients (CPCRA 058).XIII International AIDS Conference. 9–14 July 2000, Durban, South Africa. Abstract WePeB4269.
20.
RoseH., WoolleyI., HoyJ.HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism2006; 55: 90–95.
21.
CalmyA., Gayet-AgeronA., MontecuccoF.HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS2009; 23: 929–939.
